Search company, investor...

BAC

bacbv.com

Stage

Acquired | Acquired

Total Raised

$6.67M

About BAC

BAC discovers, develops and manufactures affinity ligands and affinity purification products serving the growing market of biopharmaceutical research and production. BAC's CaptureSelect purification and affinity separation products are provided for the discovery, preclinical and clinical manufacturing of therapeutic proteins, including antibodies and antibody fragments. These products enable a reduced time to market, increased purity and yield and an overall lower cost of goods for biopharmaceutical drug development. In January 2013, BAC was acquired by Life Technologies. The valuation of BAC was undisclosed. Other terms of the deal were not released.

Headquarters Location

Huizerstraatweg 28

1411 GP,

Netherlands

+31 35 69 92 614

Missing: BAC's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: BAC's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

BAC Patents

BAC has filed 28 patents.

The 3 most popular patent topics include:

  • Immune system
  • Immunology
  • Molecular biology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

4/14/2020

8/2/2022

Tires, Tractors, Minnesota state forests, Lawn and garden tractors, Pickup trucks

Grant

Application Date

4/14/2020

Grant Date

8/2/2022

Title

Related Topics

Tires, Tractors, Minnesota state forests, Lawn and garden tractors, Pickup trucks

Status

Grant

BAC Frequently Asked Questions (FAQ)

  • What is BAC's latest funding round?

    BAC's latest funding round is Acquired.

  • How much did BAC raise?

    BAC raised a total of $6.67M.

  • Who are the investors of BAC?

    Investors of BAC include Life Technologies Corporation, Stonehage Fleming and Unilever Ventures.

  • Who are BAC's competitors?

    Competitors of BAC include Kiyatec, Sirion Biotech, WaferGen Bio-systems, ZyGEM, HTG Molecular Diagnostics and 11 more.

Compare BAC to Competitors

E
EMTech

EMTech, a spin-off of BiOva, LLC, is researching, developing, and manufacturing technologies for the metabolic enhancement of the enzymes and bacteria used in the fermentation industry. The company's current products and ongoing research projects show applications that enhance productivity in the ethanol, pharmaceutical, beer, wine, and dairy industries.

O
Occam Research

The RDSP was created to help investigators identify funding opportunities and provide assistance to applicants. The RDSP staff work to stimulate research in cancer CAM and design activities that will develop the foundation of the science in cancer CAM research. RDSP programs include a series of Expert Panels on Research Methodologies in Cancer, an Invited Speakers Series, and technical assistance to help investigators prepare grant applications in cancer CAM.

N
Nanosep

Nanosep is a company with a new high performing environmentally friendly analytical technology to be used in the pharmaceutical and biotech industry. With the Nanosep technology, a customer can easily get results from complicated samples, such as blood plasma and pharmaceutical products. Both faster, with less effort and with higher precision compared to technologies available on the market today

Solidus Biosciences Logo
Solidus Biosciences

Solidus Biosciences is a company that received a STTR Phase II grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their award is funded under the American Recovery and Reinvestment Act of 2009 and their project will address further development and commercialization of a multi-enzyme lead optimization chip (Multizyme Chip) for high-throughput generation of lead compound analogs coupled with cell-based screening for the rapid identification of biologically active derivatives. Such a capability directly impacts a key bottleneck in drug discovery; namely, the efficient optimization of lead compounds to develop drugs with optimal pharmacological properties. Solidus Biosciences, Inc. proposes to combine six biocatalysis with pharmacological screening to provide rapid identification of biologically active compounds against cell-specific targets, which is a new paradigm for lead optimization. Moreover, the Multizyme Chip platform will be well-suited for lead optimization in related industries, including agrochemicals, cosmetics, and cosmeceuticals. The Solidus technology will thus improve the competitiveness and efficiency of the pharmaceutical, cosmetics, and chemical industries, and will serve as a rich source of new and improved commercial products. The broader impacts of this research are the advances that Solidus Biosciences will achieve toward generating better and safer drugs, reducing the cost to develop these drugs, and increasing the overall efficiency of the pharmaceutical industry. Solidus will generate Multizyme Chips for purchase by pharmaceutical and biotechnology companies to facilitate their lead optimization programs, particularly those involving natural product-derived and complex synthetic small molecule leads. Cryopreservation techniques developed in Phase II will enable the sale of chips and chip-handling devices produced during Phase I, and will allow seamless penetration of the Solidus technology platform into the company's target markets. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their research project aims to develop a new method for generating lead compounds by using enzymatic modification of compound sets. Availability of new methodology to generate biologically active compounds from existing molecules may enhance the success of the drug discovery process and may lead to the discovery of new and useful therapeutics. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: High-Throughput RNAi Screening of Mammalian Cells. Their research project aims to develop a system for the rapid screening of siRNAs that can inhibit genes involved in cellular responses such as hyperosmotic stress that can affect pathways of high commercial importance, including protein production. Use of hyperosmotic stress as a proof of concept system will demonstrate the feasibility of high-throughput RNAi screening and will at the same time yield results that can be used to improve monoclonal antibody production in commercial and laboratory settings Production of biopharmaceuticals such as antibodies is exquisitely responsive to the culture conditions under which the cells are grown and thus can be improved through optimizing such settings, which in turn, would affect the genes involved in the specific synthetic pathways of interest. Development of a rapid methodology to identify inhibitory RNA molecules that can inhibit genes that adversely affect yield would be of significant importance to pharmaceutical companies that produce protein therapeutics and may result in a lowering of the const of these therapeutic entities.

Kiyatec Logo
Kiyatec

Kiyatec specializes in modeling and predicting cancer patient response to drug therapies, using ex vivo 3D cell culture technology, in order to inform clinical decision-making and drive drug development. Its predictive clinical tests provide oncologists with patient-specific response profiles to the current standard of care drugs prior to treatment selection. The company was founded in 2005 and is based in Greenville, South Carolina.

Van Andel Institute Logo
Van Andel Institute

VARi has several research programs in basic sciences that will improve our understanding of the cancer process, including programs rich in functional genomics. They have a long-term commitment to the development of programs that facilitate the translation of these basic science discoveries into therapeutic strategies for attacking cancer and thus improving human health.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.